FDA is expanding its Emerging Technology Program and providing more support for new drug applications that present advanced manufacturing technologies.
Jill Wechsler
Advertisement
Jill Wechsler is BioPharm International's Washington Editor, jillwechsler7@gmail.com.
Articles by Jill Wechsler
Experts fear confusion over allocation processes, cold-chain requirements, and IT systems needed to bring a COVID-19 vaccine to market.
Regulators strive to review flood of advanced treatments while also vetting COVID-19 vaccines.
FDA announced it had issued an emergency use authorization for convalescent plasma that would make it easier to provide this treatment to COVID-19 patients.
Problems in assuring reliable drug quality and supply dampens progress in bringing lifesaving therapies to market.
Advertisement
Latest Updated Articles
Surge in Cellular and Gene Therapies Challenges FDAPublished: September 2nd 2020 | Updated:
- COVID-19 Vaccine Distribution Raises Multiple Challenges
Published: November 2nd 2020 | Updated:
- FDA Caught in Political Crossfire
Published: August 24th 2020 | Updated:
- FDA Highlights Value and Challenges of Advanced Drug Manufacturing
Published: October 21st 2021 | Updated:
- Quality Issues Offset Biomedical Advances
Published: December 2nd 2019 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
The Key Trends Driving Supply Chain Localization and Data Scrutiny in Biopharma
2
Clearing Hurdles in Sustainability, AI, and CDMO Partnerships
3
CPHI 2025 Awards Spotlight Breakthroughs in Pharmaceutical Manufacturing and API Development
4
Turning Real-World Data into Actionable Drug Development Insights With AI
5
